pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
HER2 · news · pharmadog
← back to HER2
News · HER2
189
stories
17h
GSK nabs FDA greenlight for second lung cancer asset from Nuvalent buy
biospace
1d
Roche breast cancer pill cleared by FDA
biopharma dive
1d
#CTAD26: Cognito plans FDA submission of light and sound therapy for Alzheimer’s
endpoints
2d
Lilly signs $5.9B deal with Stipple to unlock oncology targets
fiercebiotech
2d
STAT+: FDA approves new breast cancer drug, providing new option for some patients, boost for Roche
stat
7d
Neurosterix pulls in $105M for schizophrenia drug, taps Cobenfy vets
endpoints
7d
VectorY bags $83.5M for antibody gene therapies in neurodegenerative diseases
endpoints
7d
BioNTech pays $205M for FDA voucher to speed up ‘late-stage oncology pipeline’
fiercebiotech
9d
Neuroplastogen biotech Delix raises $100M Series C
endpoints
11d
Could we see 10 Chinese Big Pharmas within a decade? Some CEOs think so
fiercebiotech
15d
6 potential blockbusters that could pave China’s path to 2030 ambitions
biospace
19d
Gilead CAR-T on partial clinical hold; Agios' PDUFA date pushed back
endpoints
20d
Aspen Neuroscience lands $141M IPO, while Bambusa secures $169M
endpoints
22d
After Makary's FDA exit, biopharma exhales: Signal Survey
endpoints
23d
BioNTech, DualityBio say ADC had ‘modest’ benefit in breast cancer study
biopharma dive
23d
Aspen, Bambusa target $135M IPOs; AstraZeneca vs. Takeda in gastric cancer ADCs
endpoints
23d
BioNTech, DualityBio ponder next steps for HER2 ADC after 'modest' breast cancer results
endpoints
23d
BioNTech sees ‘limited’ benefit to ADC after phase 3 reveals modest efficacy, ILD cases
fiercebiotech
26d
ESMO 2026: Marengo's bispecific antibody shrinks 8 tumor types in Phase 2
biospace
26d
Pathos raises $237M at $3B valuation, signs Bristol Myers neuro partnership
endpoints
26d
Alnylam plans bigger study of RNA drug for Huntington’s disease
endpoints
28d
Roche’s CEO has ‘absolutely not’ changed tune on Poseida despite scrapping CAR-T from the buyout
fiercebiotech
28d
Alcon and OpenAI make acquisitions; Tezspire's latest Phase 3 win
endpoints
29d
Hologic snaps up Reveal Genomics to boost genomic diagnostic reach
fiercebiotech
29d
Biopharma Sentiment Index | Q3 2026 survey results
endpoints
Oct 19, 26
Pathos inks BMS, Tempus collabs to apply agentic AI in Alzheimer's clinical development
fiercebiotech
Oct 16, 26
Lilly interested in ibogaine investments, its neuro leader says
endpoints
Oct 15, 26
OMass Therapeutics collects $310M to chase Neurocrine, Vertex in genetic adrenal disorder
endpoints
Oct 15, 26
SimBioSys nabs FDA clearance for Nvidia-powered, MRI-derived breast cancer recurrence tool
fiercebiotech
Oct 15, 26
Iambic goes public with $150M IPO to accelerate clinical development of oncology pipeline
fiercebiotech
← prev
page 1 of 7
next →